Pfizer/Pharmacia Will Start With $39 Bil. In Worldwide Rx Sales
Pfizer/Pharmacia will begin operations with baseline annual worldwide pharmaceutical sales of approximately $39 bil., based on an analysis of the companies' 2002 year-end results
You may also be interested in...
Pfizer and Pharmacia will be alerting physicians to a new warning statement in Bextra (valdecoxib) labeling about skin and hypersensitivity reactions to the COX-2 inhibitor
Pfizer's $60 bil. offer for Pharmacia could be a landmark event in the remaking of the Pfizer image, as well as a large-scale strategic move to broaden Pfizer's product line into new specialties and deepen the pipeline
Pharmacia will pre-launch Bextra with select physicians to gather "real life experience" in advance of the COX-2 inhibitor's full launch in April